About PreciseDx
PreciseDx is a pathology and laboratory diagnostics company that has developed OncoIntelligence™, a proprietary AI platform for cancer diagnosis and risk assessment. The company's flagship product, PreciseBreast®, revolutionizes breast cancer care by combining AI-grade analysis with key clinical factors to produce an OncoIntelligence Score™ that accurately stratifies patients based on disease recurrence risk up to 8.8 years. The technology has been clinically validated in more than 1,600 breast cancer cases and analyzes cellular morphology from existing tissue samples—the same slides pathologists use for tumor grading—examining every cell to ensure accurate, quantitative data. Unlike traditional gene expression testing that can take 2-6 weeks and cost over $4,000, PreciseBreast® delivers objective results in hours at approximately 30% of the cost. Founded by Dr. Carlos Cordon-Cardo, a pioneer in molecular pathology and systems pathology, PreciseDx serves oncologists, surgeons, pathologists, payers, and patients. The company addresses a critical gap in breast cancer diagnosis where 50% of tumors are categorized as intermediate Grade 2, with high intra-observer variation (65%) in traditional grading. PreciseBreast® provides comprehensive insight into tumor phenotype and grade, refining pathologic assessment and medical decisions while offering global equity for women facing breast cancer diagnosis.
Mission & Story
Mission
Translating data into knowledge to better care for patients
Founding Story
Founded by Dr. Carlos Cordon-Cardo, widely recognized as a founding figure in molecular pathology and originator of systems pathology. As a cancer survivor himself, Dr. Cordon-Cardo pioneered an 'inside-out' framework for understanding disease, integrating anatomical pathology with molecular and systems biology. Inspired by advances in GPS and AI technologies, he reimagined diagnostic approaches through biologically informed landmarks. PreciseDx represents the culmination of his decades of research, innovation, and translational impact, with core values of Curiosity, Creative, and Community (3C).
Clinical Focus
Medical conditions and clinical areas addressed by PreciseDx.
Who It Serves
Milestones & Awards
Recent Milestones
Clinical validation completed in over 1,600 breast cancer cases. Product commercially available with portal access for professionals.
Awards & Recognition
Founder Dr. Carlos Cordon-Cardo widely recognized as founding figure in molecular pathology
Key Partnerships
Company Details
- Headquarters
- New York, NY, USA
- Employees
- 11-50
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Official Sources
Similar Companies in this Market
View all 45 →
Aiforia
Aiforia provides AI-powered digital pathology solutions for clinical diagnostics and research. The company offers cloud-based deep learning tools and CE-IVD marked clinical suites for analyzing pathology images across multiple cancer types, serving pathologists, researchers, and diagnostic laboratories worldwide.
Aignostics
Aignostics develops AI-powered pathology solutions for precision medicine, specializing in tumor microenvironment analysis from H&E-stained whole slide images. The company serves life sciences companies and academic researchers with foundation models and custom analytics services.
Aiosyn
Aiosyn develops AI-powered computational pathology software that integrates into standard digital pathology workflows. The company specializes in deep learning solutions for cancer and chronic kidney disease diagnostics, serving clinical laboratories, biopharma, and CROs.
AIxMed
AIxMed develops AI-powered computational cytology platforms for cancer detection and diagnosis. The company's flagship product AIxURO analyzes urine cytology for bladder cancer, with additional platforms in development for thyroid, cervical, and lung cancer screening.
Akoya Biosciences
Akoya Biosciences, now part of Quanterix, provides spatial biology solutions for high-plex tissue analysis. The company develops instruments, assays, and software for spatial proteomics research, enabling researchers to map biomarkers at single-cell resolution in tissue samples.
Caris Life Sciences
Caris Life Sciences is a leading precision medicine company that provides comprehensive molecular profiling for cancer patients. The company combines genomic, transcriptomic, and proteomic data with AI to deliver personalized treatment insights for oncologists and patients.
CellaVision
201-500 employees
CellaVision is a world-leading provider of digital hematology microscopy solutions covering analyzers, instruments, reagents, and software. The company automates workflows in hematology laboratories of all sizes for human and animal blood and body fluid sample analysis.
Clever Culture Systems
Clever Culture Systems develops AI-powered automated microbiology culture plate reading technology for pharmaceutical and clinical laboratories. Their flagship product, APAS Independence, automates the imaging, interpretation, and reporting of microbial growth on culture plates.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.